Pfizer Ltd Q1 FY27 Results Analysis: EBITDA Margin Expands 307 bps, Revenue Grows 8.3%

Cofacto Research Updated July 28, 2026 2 min read

Positive

Pfizer Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 653.17 Cr (+8.31% YoY) and PAT growth of +6.63% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details

Results date	July 28, 2026
Quarter	Q1 FY 2026-2027
Revenue (Q1)	Rs. 653.17 Cr (+8.31% YoY)
PAT (Q1)	Rs. 204.47 Cr (+6.63% YoY)
EBITDA margin	37.90% (+307 bps YoY)
EPS (Q1)	Rs. 44.69 (+6.63% YoY)
Market cap	Rs. 21,630.46 Cr
CMP	Rs. 4,728.20

Quarter Snapshot

Q1 FY27 results showed 8.31% revenue growth and 307 bps EBITDA margin expansion, driven by cost restructuring and operating leverage. The company is debt-free with strong cash reserves. Key concerns include gross margin pressure from pricing headwinds and lack of explicit guidance.

Key Investment Insights

Key Positives

Revenue grew 8.31% YoY to Rs.653.17 Cr, with total expenses growing only 2.59% YoY.
EBITDA margin expanded 307 bps YoY to 37.90%, driven by lower employee costs and cost discipline.
PAT grew 6.63% YoY to Rs.204.47 Cr, with EPS at Rs.44.69.
Company remains debt-free with cash reserves of ~Rs.3,111 Cr (FY26).

Risk Factors

Gross materials cost ratio (net of inventory) increased ~173 bps YoY to 36.76% of revenue, indicating pricing headwinds from DPCO and trading mix shift.
Other income declined 33.24% YoY to Rs.44.84 Cr, impacting total income growth.
No explicit financial guidance provided for FY27, reducing visibility.